SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
Rattachement africain : us, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Currently approved COVID-19 vaccines prevent symptomatic infection, hospitalization, and death of the disease. However, the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants raises concerns of reduced vaccine effectiveness and increased risk of infection. Repeated homologous booster in elderly individuals and immunocompromised patients is considered to solve severe form of disease caused by new SARS-CoV-2 variants but cannot protect completely against breakthrough infection. In our previous study we assessed the immunogenicity of an adenovirus-based vaccine expressing SARS-CoV-2-S1 (Ad5.S1) in mice, resulting in that a single immunization with Ad5.S1, via subcutaneously injection or intranasal delivery, induced robust humoral and cellular immune responses [1]. As a follow up study, here we showed that vaccinated mice had high titers of anti-S1 antibodies at one year after vaccination compared to PBS immunized mice. Furthermore, one booster dose of non-adjuvanted recombinant S1Beta (rS1Beta) subunit vaccine was effective in stimulating strong long-lived S1-specific immune responses and inducing significantly high neutralizing antibodies against the Wuhan, Beta, and Delta strain with 3.6- to 19.5-fold change increases. Importantly, the booster dose elicits cross-reactive antibody responses resulting in ACE2 binding inhibition against spike of SARS-CoV-2 variants (Wuhan, Alpha, Beta, Gamma, Delta, Zeta, Kappa, New York, India) as early as two-week post-boost injection, persisting over 28 weeks after a booster vaccination. Interestingly, levels of neutralizing antibodies were correlated with not only level of S1-binding IgG but also level of ACE2 inhibition in the before- and after-booster serum samples. Our findings show that S1 recombinant protein subunit vaccine candidate as a booster has potential to offer cross-neutralization against broad variants, and has important implications for vaccine control of new emerging breakthrough SARS-CoV-2 variants in elderly individuals primed with adenovirus-based vaccine like AZD1222 and Ad26.COV2.S.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
- Date Crossref
- 26/10/2022
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Pittsburgh Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Pittsburg State University pays non établi dans la noticeUniversité ou école supérieure
-
Policlinico San Matteo Fondazione pays non établi dans la noticeÉtablissement de santé
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
University of Pavia Department of Clinical pays non établi dans la noticeUniversité ou école supérieure
-
UPMC Health System pays non établi dans la noticeÉtablissement de santé
-
UPMC Hillman Cancer Center pays non établi dans la noticeStructure de recherche
-
University of Pittsurgh Graduate School of Pulic Health Department of Infectious Diseases and Microiology pays non établi dans la noticeUniversité ou école supérieure
-
IRCCS Policlinico San Matteo Microbiology and Virology Department pays non établi dans la noticeÉtablissement de santé
-
Moleular Virology Unit pays non établi dans la noticeInstitution
-
University o Pittsburgh School o Medicine Department o Medicine pays non établi dans la noticeUniversité ou école supérieure
-
University of Pittsburh School of Medicine Department of Microbioloy and Molecular Genetics pays non établi dans la noticeUniversité ou école supérieure
Department of Surgery — University of Pittsburgh, Pittsburg State University et Policlinico San Matteo Fondazione, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.